Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

NCT06533527 on ClinicalTrials.gov · last registry update 2025-12-05

Finished 20 May 2025, after enrolling 69 people. Primary outcome, as filed: Presence of RGV (Residual Gastric Volume) in Stomach. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 69
Started: 2024-07-31
Primary completion: 2025-05-20 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Presence of RGV (Residual Gastric Volume) in Stomach

Conditions studied

Diabetes Mellitus, Type 2 · Obesity · Gastroparesis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.